Paratek Stock Analysis

PRTK -  USA Stock  

USD 5.55  0.12  2.21%

The recent plunge in stock price may encourage traders to take a closer look at the company as it is trading at a share price of 5.55 on 1,300,519 in trading volume. The company executives have failed to build on market volatilities in July. However, diversifying your overall positions with Paratek Pharma may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.48. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Paratek Pharma partners.
Please check Your Equity Center.

Search Stock Analysis 

The Paratek Pharma stock analysis report makes it easy to digest most publicly released information about Paratek Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Paratek Stock analysis module also helps to analyze the Paratek Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Paratek Stock Analysis Notes

About 56.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.09. Paratek Pharma recorded a loss per share of 2.18. The entity next dividend is scheduled to be issued on the 31st of October 2014. The firm had 1:12 split on the 31st of October 2014. Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. The company was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 196 people. To find out more about Paratek Pharma contact Michael Bigham at 650 228-1088 or learn more at

Paratek Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Paratek Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Paratek Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Paratek Pharma generates negative expected return over the last 90 days
Paratek Pharma has high historical volatility and very poor performance
Paratek Pharma has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 55.43 M. Net Loss for the year was (87.27 M) with profit before overhead, payroll, taxes, and interest of 14.35 M.
Paratek Pharma currently holds about 103.45 M in cash with (94.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.2.
Paratek Pharma has a frail financial position based on the latest SEC disclosures
Roughly 56.0% of the company shares are owned by institutional investors
Latest headline from Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635 - Benzinga - Benzinga

Paratek Pharma Upcoming and Recent Events

Earnings reports are used by Paratek Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Paratek Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Paratek Largest EPS Surprises

Earnings surprises can significantly impact Paratek Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Paratek Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 250.53 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Paratek Pharma's market, we take the total number of its shares issued and multiply it by Paratek Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Paratek Profitablity

Paratek Pharma's profitability indicators refer to fundamental financial ratios that showcase Paratek Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Paratek Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Paratek Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Paratek Pharma's profitability requires more research than a typical breakdown of Paratek Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (157.44) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (119.33) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.19.
Last ReportedProjected for 2021
Return on Investment(40.89) (44.12) 
Return on Average Assets(45.12) (48.68) 
Return on Average Equity-3.7 K-3.8 K

Management Efficiency

The entity has return on total asset (ROA) of (21.04) % which means that it has lost $21.04 on every $100 spent on asset. This is way below average. Paratek Pharma management efficiency ratios could be used to measure how well paratek pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -44.12. The current Return on Average Assets is estimated to decrease to -48.68. The current Total Liabilities is estimated to increase to about 301.1 M. The current Current Liabilities is estimated to increase to about 25.8 M

Technical Drivers

As of the 5th of August, Paratek Pharma holds the risk adjusted performance of (0.06), and Coefficient Of Variation of (1,065). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Paratek Pharma, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Paratek Pharma, which can be compared to its competitors. Please check Paratek Pharma information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Paratek Pharma is priced some-what accurately, providing market reflects its current price of 5.55 per share. Given that Paratek Pharma has jensen alpha of (0.44), we recommend you to check out Paratek Pharma's recent market performance to make sure the company can sustain itself at a future point.

Paratek Pharma Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Paratek Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Paratek Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Paratek Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Paratek Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Paratek Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Paratek Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Baylorhenry Minnie over a month ago via Macroaxis 
Acquisition by Baylorhenry Minnie of 12800 shares of Paratek Pharma subject to Rule 16b-3
Brenner Randall B over a month ago via Macroaxis 
Sale by Brenner Randall B of 9978 shares of Paratek Pharma
Hoffmann Rolf K over three months ago via Macroaxis 
Acquisition by Hoffmann Rolf K of 7000 shares of Paratek Pharma subject to Rule 16b-3
Brenner Randall B over six months ago via Macroaxis 
Sale by Brenner Randall B of 8760 shares of Paratek Pharmaceuticals
Timothy Franson over six months ago via Macroaxis 
Acquisition by Timothy Franson of 5000 shares of Paratek Pharmaceuticals subject to Rule 16b-3
Michael Bigham over six months ago via Macroaxis 
Sale by Michael Bigham of 26250 shares of Paratek Pharmaceuticals
Brenner Randall B over six months ago via Macroaxis 
Sale by Brenner Randall B of 8357 shares of Paratek Pharmaceuticals
Evan Loh over six months ago via Macroaxis 
Exercise or conversion by Evan Loh of 479 shares of Paratek Pharmaceuticals subject to Rule 16b-3
New Enterprise Associates 10 L P over a year ago via Macroaxis 
Conversion by New Enterprise Associates 10 L P of 1660458 shares of Paratek Pharmaceuticals
Barrett M James over a year ago via Macroaxis 
Conversion by Barrett M James of 1660458 shares of Paratek Pharmaceuticals
William Haskel over a year ago via Macroaxis 
Sale by William Haskel of 4666 shares of Paratek Pharmaceuticals
Brenner Randall B over a year ago via Macroaxis 
Sale by Brenner Randall B of 6198 shares of Paratek Pharmaceuticals

Paratek Pharma Predictive Daily Indicators

Paratek Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Paratek Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Paratek Pharma Forecast Models

Paratek Pharma time-series forecasting models is one of many Paratek Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Paratek Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Paratek Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Paratek Pharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Paratek shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Paratek Pharma. By using and applying Paratek Stock analysis, traders can create a robust methodology for identifying Paratek entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(17.20) (18.56) 
EBITDA Margin(16.42) (17.72) 
Gross Margin 81.56  76.72 
Profit Margin(17.73) (19.13) 
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. The company was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 196 people.

Current Paratek Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Paratek analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Paratek analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Paratek Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Paratek analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Paratek stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Paratek Pharma, talking to its executives and customers, or listening to Paratek conference calls.
Paratek Analyst Advice Details

Paratek Stock Analysis Indicators

Paratek Pharma stock analysis indicators help investors evaluate how Paratek Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Paratek Pharma shares will generate the highest return on investment. By understating and applying Paratek Pharma stock analysis, traders can identify Paratek Pharma position entry and exit signals to maximize returns.
Quick Ratio5.31
Fifty Two Week Low4.11
Revenue Growth107.40%
Shares Short Prior Month4.26M
Average Daily Volume Last 10 Day243.14k
Average Daily Volume In Three Month558.93k
Shares Percent Shares Out9.36%
Gross Margins40.46%
Short Percent Of Float9.69%
Forward Price Earnings-267.00
Float Shares40.49M
Fifty Two Week High11.24
Enterprise Value To Ebitda-7.17
Fifty Day Average6.74
Two Hundred Day Average7.49
Enterprise Value To Revenue8.47
Please check Your Equity Center. Note that the Paratek Pharma information on this page should be used as a complementary analysis to other Paratek Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Paratek Stock analysis

When running Paratek Pharma price analysis, check to measure Paratek Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Paratek Pharma is operating at the current time. Most of Paratek Pharma's value examination focuses on studying past and present price action to predict the probability of Paratek Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Paratek Pharma's price. Additionally, you may evaluate how the addition of Paratek Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Fundamental Analysis
View fundamental data based on most recent published financial statements
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
The market value of Paratek Pharma is measured differently than its book value, which is the value of Paratek that is recorded on the company's balance sheet. Investors also form their own opinion of Paratek Pharma's value that differs from its market value or its book value, called intrinsic value, which is Paratek Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Paratek Pharma's market value can be influenced by many factors that don't directly affect Paratek Pharma underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Paratek Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Paratek Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Paratek Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.